pazopanib

Type: Keyphrase
Name: pazopanib
First reported 8 hours ago - Updated 2 hours ago - 2 reports

Forum Post: Re: pazopanib.. my journey

Hi Tony I started on pazopanib on 6th September symptoms I have had so far are little nauseous occasionally, hair colour changing (but was anyway) headache started after couple of weeks take usual headache tablets (worse first thing in morning) have also ... [Published Macmillan Cancer Support - 2 hours ago]
First reported 15 hours ago - Updated 8 hours ago - 1 reports

GSK looks for £1 billion savings and plans IPO for ViiV

GlaxoSmithKline has announced major restructuring plans aimed at saving £1 billion within three years and a possible initial public offering of ViiV Healthcare after posting another lacklustre set of financials.Third-quarter sales fell 10% to £5.65 billion, ... [Published Pharma Times - 15 hours ago]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Forum Post: RE: headache on pazopanib

Living with incurable cancer - patients onlyThis group is specifically for anyone with an incurable or terminal diagnosis. Whether you need to talk about dying, or about making the most of your life, you can discuss your feelings openly here, without ... [Published Macmillan Cancer Support - Oct 18 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

Forum Post: headache on pazopanib

For people living with incurable cancer onlyThis group is aimed only at people who have had an incurable diagnosis themselves, as we have had feedback that they would like a safe space to share their feelings openly among themselves.If you have a loved ... [Published Macmillan Cancer Support - Oct 18 2014]
Entities: pazopanib, Cancer
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

OXiGENE announces first patient enrollment in Phase Ib/II ovarian cancer study

OXiGENE, Inc., a biopharmaceutical company, has announced the first patient enrollment in a Phase Ib/II clinical study that will evaluate fosbretabulin in combination with Votrient in patients with recurrent ovarian cancer. The randomized, controlled ... [Published Individual.com - Oct 10 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 1 reports

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma

Research articleRobert J Canter , Erik Ames , Stephanie Mac , Steven K Grossenbacher , Mingyi Chen , Chin-Shang Li , Dariusz Borys , Rachel C Smith , Joe Tellez , Thomas J Sayers , Arta M Monjazeb and William J MurphyBMC Cancer 2014, 14 :756doi:10.11 ... [Published BMC - Oct 10 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Findings from GlaxoSmithKline Provides New Data about Age-Related Macular Degeneration (Clinical Evaluation Of Pazopanib Eye Drops In Healthy...

Findings from GlaxoSmithKline Provides New Data about Age-Related Macular Degeneration (Clinical Evaluation Of Pazopanib Eye Drops In Healthy Subjects And In Subjects With Neovascular Age-related Macular Degeneration)By a News Reporter-Staff News Editor ... [Published 4 Traders - Oct 09 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Findings from GlaxoSmithKline Has Provided New Data on Renal Cell Carcinoma (Persistence and Compliance with Pazopanib in Patients with Advanced...

Findings from GlaxoSmithKline Has Provided New Data on Renal Cell Carcinoma (Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a US Administrative Claims Database)By a News Reporter-Staff News Editor at Clinical ... [Published 4 Traders - Oct 03 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

[Correspondence] Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye

Many tyrosine-kinase inhibitors show pH-dependent solubility in the physiologically relevant pH range, which might be susceptible to gastric pH-dependent drug—drug interactions when co-administered with acid-suppressive agents. Such drug-drug interactions ... [Published Lancet Oncology - Oct 01 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

News Maintenance pazopanib in ovarian cancer

Related Biotechnology, Pharmaceutical and Healthcare NewsAngiogenesis has been shown to play an important part in the growth of ovarian cancer and VEGF is a key driver of the process.Original Article: [News] Maintenance pazopanib in ovarian cancerNEXT ... [Published BioPortfolio - Sep 27 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Forum Post: Pazopanib and the side effects

I had kidney cancer had the whole kidney removed was good for nearly 2 yrs. Then was then told it had spread to the Carina with 4 small lumps in my right lung not operable was put on Pazopanib 23 months ago.But after my last 2 scans they have gone and ... [Published Macmillan Cancer Support - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 2 reports

Forum Post: RE: third line treatment

For everything about chemotherapy, being treated and side effects. Tell others about your experiences and get answers to your questions.third line treatmentPosted by harmonica on25 Sep 2014 6:43 AMHi all.I start pazopanib in a few weeks.I wondered if ... [Published Macmillan Cancer Support - Sep 25 2014]

Quotes

...of knowledge about fosbretabulin as part of a non-chemotherapeutic regimen in treating ovarian cancer," said Dai Chaplin, Ph D , CEO at OXiGENE. "We are delighted to support this important study, along with others, as it provides OXiGENE an important development opportunity in Europe and delivers on our strategy to leverage collaborations that advance the clinical knowledge about fosbretabulin."
"I keep thinking of the children, you know. We've got to keep pressing on" Stone explained

More Content

All (47) | News (39) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Forum Post: Re: pazopanib.. my journey [Published Macmillan Cancer Support - 2 hours ago]
Forum Post: pazopanib.. my journey [Published Macmillan Cancer Support - 8 hours ago]
GSK looks for £1 billion savings and plans IPO ... [Published Pharma Times - 15 hours ago]
GlaxoSmithKline’s third-qtr results not as bad ... [Published Pharma Letter - 16 hours ago]
Welsh Cancer Plan: health boards 'must be held ... [Published Pharma Times - Oct 19 2014]
Forum Post: RE: headache on pazopanib [Published Macmillan Cancer Support - Oct 18 2014]
Forum Post: headache on pazopanib [Published Macmillan Cancer Support - Oct 18 2014]
NANETS: Axitinib Yields "Promising" Progression... [Published Chemotherapy Advisor - Oct 14 2014]
Axitinib Shows Promise in Carcinoid Tumors [Published OncLive - Oct 11 2014]
OXiGENE announces first patient enrollment in P... [Published Individual.com - Oct 10 2014]
Anti-proliferative but not anti-angiogenic tyro... [Published BMC - Oct 10 2014]
Cancer Drugs Fund in England: Plugging a Gap in... [Published American Journal of Public Health - Oct 09 2014]
Findings from GlaxoSmithKline Provides New Data... [Published 4 Traders - Oct 09 2014]
OXiGENE Announces First Patient Enrolled in Pha... [Published GlobeNewswire: Acquisitions News - Oct 07 2014]
Findings from GlaxoSmithKline Has Provided New ... [Published 4 Traders - Oct 03 2014]
[Correspondence] Drug interactions between tyro... [Published Lancet Oncology - Oct 01 2014]
Durable Responses Observed with Nivolumab in Pr... [Published OncLive - Sep 30 2014]
Forum Post: RE: foods to avoid [Published Macmillan Cancer Support - Sep 30 2014]
News Maintenance pazopanib in ovarian cancer [Published BioPortfolio - Sep 27 2014]
Forum Post: Pazopanib and the side effects [Published Macmillan Cancer Support - Sep 26 2014]
The Resurgence of Interest in Immune Therapy fo... [Published Chemotherapy Advisor - Sep 25 2014]
Forum Post: RE: third line treatment [Published Macmillan Cancer Support - Sep 25 2014]
Forum Post: third line treatment [Published Macmillan Cancer Support - Sep 25 2014]
EORTC presentations at ESMO 2014 Congress [Published Press News.org - Sep 23 2014]
Forum Post: RE: Advanced kidney cancer spread p... [Published Macmillan Cancer Support - Sep 15 2014]
Forum Post: Advanced kidney cancer spread pancr... [Published Macmillan Cancer Support - Sep 15 2014]
Uterine Cancer Pipeline Review H2 2014 [Published BioPortfolio - Sep 15 2014]
TRACON Pharmaceuticals Initiates Phase 2 Clinic... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Cancer Drugs Fund receives boost but will no lo... [Published PharmaGossip - Sep 01 2014]
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cancer Drugs Fund receives boost but will no lo... [Published PharmaGossip - Sep 01 2014]
Cancer Drugs Fund receives boost but will no longer fund “overpriced” drugsBMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g5382 (Published 01 September 2014)Cite this as: BMJ 2014;349:g5382Nigel HawkesThe Cancer Drugs Fund has been given a 40% increase ...
The Texas Medical Board vs. Stanislaw Burzynski... [Published ScienceBlogs : Combined Feed - Jul 14 2014]
There’s a point I feel that I have have to make briefly as I begin this post. Basically, this might look familiar, but given that I was at TAM Wednesday through Sunday, I didn’t have time to produce two separate posts, and this is important enough ...
The Texas Medical Board vs. Stanislaw Burzynski... [Published Science-Based Medicine - Jul 14 2014]
As I begin this post, I’m no a miserably crowded, hot, stinky flight winging my way home from TAM . This puts me in the perfect mood to write about my bête noire to conquer all bêtes noires, namely Stanislaw Burzynski, the Polish expat doctor who ...
Old member, new name? [Published HealthBoards - Jun 05 2014]
When I was diagnosed with follicular ThyCa back in late 2005 I posted under my first and last name but after several years of inactivity I came back and found that Admin had changed my login to my first name along with a number. After several years more ...
Overall Survival in Renal-Cell Carcinoma with P... [Published The New England Journal of Medicine: Hematology ... - May 01 2014]
To the Editor: In the August 22 issue, we reported on a phase 3 trial showing the noninferiority, with respect to progression-free survival, of pazopanib versus sunitinib as first-line treatment for clear-cell, metastatic renal-cell carcinoma, as assessed ...
1

Press Releases

sort by: Date | Relevance
OXiGENE Announces First Patient Enrolled in Pha... [Published GlobeNewswire: Acquisitions News - Oct 07 2014]
TRACON Pharmaceuticals Initiates Phase 2 Clinic... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.